HSIC

Business Context and Reporting Period

Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 27, 2003
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. The company operates through two segments: Healthcare Distribution (dental, medical, and international) and Technology (practice management software and value-added services). It serves over 425,000 customers worldwide, including dental practices, physician offices, and veterinary clinics.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 18.7% to $3.35 billion, driven primarily by an 18.9% increase in the Healthcare Distribution segment.
  • Medical: Sales grew 22.3% due to increased sales to physician offices and alternate care markets.
  • International: Sales grew 31.9% due to acquisitions, favorable exchange rates, and account penetration in France, Spain, and Austria.
  • Dental: Sales grew 11.2% driven by the "Privileges" loyalty program and an acquisition.
• Profitability: Net income rose 16.5% to $137.5 million. Operating income increased 18.6% to $233.7 million.
  • Margins: Gross margin decreased slightly to 27.6% from 28.1%, primarily due to higher sales of lower-margin injectable pharmaceuticals in the medical business.
  • Expenses: Selling, general, and administrative (SG&A) expenses increased 15.8% but decreased as a percentage of sales from 21.2% to 20.7% due to infrastructure leverage.
• Acquisitions: Completed 8 acquisitions in 2003, including Hager Dental GmbH and Colonial Surgical Supply, Inc.
• Divestiture: Sold PMA Bode GmbH (x-ray film distribution) in Q3 2003, recognizing a $2.0 million loss on the sale of discontinued operations.

Guidance, Outlook, and Risks

• Strategic Acquisitions: The company is awaiting regulatory approval for the acquisition of demedis GmbH and Euro Dental Holding GmbH (EDH) for approximately 255 million euros. These deals are expected to double the net sales of international operations. A $150 million bridge loan has been secured to facilitate the transaction.
• Capital Allocation: The company repurchased 1.335 million shares of common stock in 2003 at an average price of $46.26. It expects to invest $35–$40 million in capital projects in 2004.
• Market Risks:
  • Competition: Highly competitive industry with pressure from manufacturers selling directly to end-users and consolidation among distributors.
  • Regulatory: Subject to extensive government regulation regarding pharmaceuticals and medical devices (e.g., FDA, DEA). The new Medicare Prescription Drug Act may impact volume demand.
  • Legal: Pending product liability claims (16 cases, 11 involving latex gloves) and a purported class action in New Jersey regarding vaccine sales. Management believes these are covered by insurance or will not materially harm financial condition.
  • Foreign Exchange: International operations expose the company to currency fluctuations, though hedging programs are in place.

Investor Verification Checklist

• Acquisition Closing: Verify the regulatory approval status and closing timeline for the demedis and EDH acquisitions, which are critical to the international growth strategy.
• Margin Pressure: Monitor the mix of medical product sales, specifically the proportion of lower-margin injectable pharmaceuticals, to assess future gross margin trends.
• Legal Exposure: Track the status of the Texas class action (decertified but individual claims remain) and the New Jersey vaccine class action to ensure no material liability emerges.
• Debt Structure: Review the terms of the $150 million bridge loan and the refinancing strategy for the pending European acquisitions.
• Working Capital: Observe the trend in accounts receivable and inventory levels, which increased in 2003 and impacted operating cash flow.